Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Vet Res. 2004 Mar;65(3):277-8.

Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies.

Author information

  • 1Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.

Abstract

OBJECTIVE:

To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.

ANIMALS:

15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.

PROCEDURE:

Dogs were assigned to 3 treatment groups (control, 3X, or 5X group) in a randomized block design on the basis of the maximal ivermectin-sensitivity score obtained during preliminary screening. Dogs in groups 3X and 5X were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.

RESULTS:

None of the dogs had clinical abnormalities during the study period.

CONCLUSIONS AND CLINICAL RELEVANCE:

Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose.

PMID:
15027671
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk